RSS

Synpromics

Gene control company, Synpromics, has been awarded a £1.9 million research and development grant from Scottish Enterprise, which will be used to expand its R&D programmes in gene regulation for cell and gene medicines. Read more

News

Gene control company, Synpromics, has announced it will collaborate with the University College London (UCL) Great Ormond Street Institute of Child Health for the development of novel gene therapies for pathologies affecting the haematopoietic system Read more

News

Gene control company, Synpromics, has revealed its collaboration with University College London (UCL) for the generation of a range of synthetic gene promotors for the central nervous system (CNS) to develop a therapy for Parkinson’s disease. Read more

News

Synpromics has won the ‘best emerging UK synthetic biotech company’ at the annual OBN Awards, which celebrate innovation and achievement across the UK life sciences industry. Read more

News

Gene control company, Synpromics, and life sciences company, Solid Biosciences, have entered into a research partnership for the development of new treatment options for Duchenne muscular dystrophy (DMD). Read more

News

Synthetic promotor and gene control company, Synpromics, has raised £5.2 million of new investment. The funds were raised from existing investors. Read more

News